India’s First Coronavirus Vaccine Covaxin Gets Human Trial Approval

Hyderabad : India’s first indigenous COVID-19 vaccine has been approved by the Indian Drug Controller General (DCGI) for human trials. Vaccine named ‘Covaxin’ has been developed by Bharat Biotech in association with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

The first and second phase of this vaccine will begin in the country from next month. The company said in a statement that the cooperation of ICMR and NIV was important in the development of the vaccine.

Drug manufacturers around the world are engaged in an effort to develop a vaccine against the coronavirus. A leading manufacturer of vaccines and generic drugs, India hopes to play an important role in this race, with many institutions working with various drugs. Recently, it was said on behalf of the government that 30 groups are engaged in the work of vaccines.

Coronavirus continues to wreak havoc in India, although the government has issued guidelines for the second phase of unlock i.e. Unlock-2. The new guidelines allow for more activities to be opened outside the containment zones.

The new guidelines will be effective from 1 July 2020. The process of opening the economy in a phased manner has been carried forward. The new guidelines issued are based on feedback received from states and union territories and extensive consultations with the respective central ministries and departments.